Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Authors:
- 20 July 2024
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (5) , 984-986
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialChinese Medical Journal, 2023
- The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019World Allergy Organization Journal, 2021
- Atopic dermatitis: an expanding therapeutic pipeline for a complex diseaseNature Reviews Drug Discovery, 2021
- The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*British Journal of Dermatology, 2021
- Prevalence and Incidence of Atopic Dermatitis: A Systematic ReviewActa Dermato-Venereologica, 2020